← boardnext 2027-04
NKTX
Nkarta, Inc.distress 3/10 · well-funded / low risk$2.32-4%today-37% from 52w high
Oncology 1
Lead: Systemic Sclerosis · target CD19
Revenue
pre-revenue
Liquidity
$264M
Runway
3.0 yrs
Shares 1y
+1%
Price & events
-3.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.7%
1D
-10.8%
1W
-23.4%
1M
-22.1%
3M
-6.8%
6M
+4.0%
1Y
-66.1%
2Y
-92.8%
5Y
-96.1%
All
Overview
- Market Cap
- $165.99M
- Volume
- 108.84K
- 52 Week Range
- $1.73 – $3.67
- Total Shares
- 71.55M
- Float Shares
- 60.44M
- Short %
- 5.91%
- % Held by Insiders
- 4.88%
- % Held by Institutions
- 80.75%
- RVOL
- 0.15x
- Beta
- 0.92
Pipeline stages · 1 programs
NKX019, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04 Estimated 50% readout ~2027-05-16 | Phase 1/2 | NKX019, Fludarabine, Cyclophosphamide | Lupus Nephritis, Primary Membranous Nephropathy | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-11-15 | Phase 1/2 | NKX019, Fludarabine, Cyclophosphamide | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis | — | recruiting |
| 2025-03-31 | Phase 1 | NKX019 | Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma | 150 | active not recruiting |
Catalyst news & presentations · 2
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2025readoutNKX019 · Preliminary clinical data from Ntrust-1 (lupus nephritis) and Ntrust-2 (systemic sclerosis, IIM, ANCA-associated vasculitis) trials.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+388% upside) · 6 analysts
- 2026-05-13NeedhamBuy
- 2026-03-31MizuhoOutperform
- 2026-03-26NeedhamBuy
- 2025-11-11StifelBuy
- 2025-08-14StifelBuy
- 2025-08-13NeedhamBuy
Competitors — CD19
Recent news
- 2026-07-23Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development - GlobeNewswire
- 2026-07-16Nkarta Inc. (NKTX) Declines 4.9% as Biotech Headwinds Persist — Key Support in Focus - TICK Divergence - dars.gov.et
- 2026-07-04Nkarta (NKTX) Stock Analysis Report | Financials & Insights - Benzinga España
- 2026-06-30Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
- 2026-06-26Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy - Stock Titan
- 2026-06-26Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
- 2026-06-26Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
- 2026-06-26Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - The Manila Times
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.